Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody

被引:35
作者
Sharkey, RM
Karacay, H
Chang, CH
McBride, WJ
Horak, ID
Goldenberg, DM
机构
[1] Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA
[2] IBC Pharmaceut Inc, Morris Plains, NJ USA
[3] Immunomed Inc, Morris Plains, NJ USA
关键词
bispecific antibody; CD20; non-Hodgkin's lymphoma; pretargeting; radioimmunotherapy;
D O I
10.1038/sj.leu.2403751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A comparison of the therapeutic efficacy of a new bispecific monoclonal antibody (bsMAb)-pretargeting system vs the conventional direct targeting modality was undertaken. A bsMAb was made by coupling the Fab' of a humanized anti-CD20 antibody to the Fab' of a murine antibody directed against the peptide histamine-succinyl-glycine (HSG). The tumor targeting of the bsMAb was separated from the subsequent delivery of the radionuclide-bearing HSG peptide conjugated with In-111 or Y-90. Nude mice bearing s.c. Ramos human B-cell lymphomas were injected with the bsMAb and then, 48 h later, In-111/Y-90-HSG peptide was given. At 3 h postinjection, tumor/blood ratios for pretargeted In-111-HSG-peptide were similar to that observed with the directly conjugated In-111-anti-CD20 IgG at its highest level on day 7, but by day 1, tumor/blood ratios were about 10-fold higher than the IgG. Tumors progressed rapidly in animals given 800 mu Ci of Y-90-HSG peptide alone, whereas 5/10 animals in the group pretargeted by the anti-CD20 bsMAb were tumor-free 18 weeks later. The antitumor response in animals administered the pretargeted Y-90-HSG peptide was also significantly superior to treatment with the directly radiolabeled Y-90-anti-CD20 IgG, whether given as a single injection (P<0.007) or as a divided dose (P=0.016). This bsMAb-pretargeting procedure significantly improves the therapeutic response of targeted radionuclides in non-Hodgkin's lymphoma, warranting further development of this method of radioimmunotherapy.
引用
收藏
页码:1064 / 1069
页数:6
相关论文
共 50 条
[41]   Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma [J].
Betting, David J. ;
Yamada, Reiko E. ;
Kafi, Kamran ;
Said, Jonathan ;
van Rooijen, Nico ;
Timmerman, John M. .
JOURNAL OF IMMUNOTHERAPY, 2009, 32 (06) :622-631
[42]   CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma [J].
Manzke, O ;
Titzer, S ;
Tesch, H ;
Diehl, V ;
Bohlen, H .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) :198-202
[43]   Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma [J].
Kato, Jason ;
O'Donnell, Robert T. ;
Abuhay, Mastewal ;
Tuscano, Joseph M. .
ONCOIMMUNOLOGY, 2012, 1 (09) :1469-1475
[44]   Near-Infrared Fluorescence Imaging of Non-Hodgkin's Lymphoma CD20 Expression Using Cy7-Conjugated Obinutuzumab [J].
Lin, Xinfeng ;
Zhu, Hua ;
Luo, Zheng ;
Hong, Ye ;
Zhang, Hong ;
Liu, Xijuan ;
Ding, Huirong ;
Tian, Huifang ;
Yang, Zhi .
MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (06) :877-887
[45]   Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review [J].
Kennedy, GA ;
Tey, SK ;
Cobcroft, R ;
Marlton, P ;
Cull, G ;
Grimmett, K ;
Thomson, D ;
Gill, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :412-416
[46]   Near-Infrared Fluorescence Imaging of Non-Hodgkin’s Lymphoma CD20 Expression Using Cy7-Conjugated Obinutuzumab [J].
Xinfeng Lin ;
Hua Zhu ;
Zheng Luo ;
Ye Hong ;
Hong Zhang ;
Xijuan Liu ;
Huirong Ding ;
Huifang Tian ;
Zhi Yang .
Molecular Imaging and Biology, 2014, 16 :877-887
[47]   Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging [J].
Lee, Seung-Cheol ;
Poptani, Harish ;
Pickup, Stephen ;
Jenkins, W. Timothy ;
Kim, Sungheon ;
Koch, Cameron J. ;
Delikatny, E. James ;
Glickson, Jerry D. .
NMR IN BIOMEDICINE, 2010, 23 (06) :624-632
[48]   Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan [J].
Blakkisrud, Johan ;
Londalen, Ayca ;
Martinsen, Anne C. T. ;
Dahle, Jostein ;
Holtedahl, Jon E. ;
Bach-Gansmo, Tore ;
Holte, Harald ;
Kolstad, Arne ;
Stokke, Caroline .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) :48-54
[49]   Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma [J].
Boucek, JA ;
Turner, JH .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (04) :458-469
[50]   Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma [J].
Jan A. Boucek ;
J. Harvey Turner .
European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 :458-469